Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study
M Santoni, F Massari, ZW Myint, R Iacovelli, M Pichler… - Targeted Oncology, 2023 - Springer
Background Immuno-oncology combinations have achieved survival benefits in patients
with metastatic renal cell carcinoma (mRCC). Objective The ARON-1 study (NCT05287464) …
with metastatic renal cell carcinoma (mRCC). Objective The ARON-1 study (NCT05287464) …
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell …
H Ishihara, Y Nemoto, H Tachibana, T Ikeda… - Clinical Genitourinary …, 2024 - Elsevier
Background It remains unclear whether kidney function affects outcomes following immune
checkpoint inhibitor (ICI)-based combination therapy for advanced renal cell carcinoma …
checkpoint inhibitor (ICI)-based combination therapy for advanced renal cell carcinoma …
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for …
H Ishihara, K Omae, Y Nemoto, R Ishiyama… - International Journal of …, 2024 - Springer
Background There are few comparative studies on dual immune checkpoint inhibitors
(ICIs)(ie, IO-IO) and combination therapies comprising ICIs plus tyrosine kinase inhibitors …
(ICIs)(ie, IO-IO) and combination therapies comprising ICIs plus tyrosine kinase inhibitors …
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
A Poprach, I Kiss, M Stanik, T Barusova… - Targeted Oncology, 2023 - Springer
Background Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly
expanding, and immunotherapy using checkpoint inhibitors is a first-or second-line option …
expanding, and immunotherapy using checkpoint inhibitors is a first-or second-line option …